Theralase Technologies Inc (TLTFF)

[123414]

Theralase Commences Collaborative Research with National Microbiology Laboratory for Development of Coronavirus Vaccine
April 9, 2021


Megan in my view, the study has already been Improved. After the "dirty dozen" were undertreated the treatment protocol was returned to the Ph 1 67% cr study protocol. So patients 13 -30 got the proper dose and that info is now just showing up in the pr data.

The last batch of data released has now confirmed the improvements made directly after the first treated 12 patients from phase 2 has bore fruit.

And is currently at unprecedented levels of Cr with exception to the Theralse Phase 1 study. In other words no one beats Theralase rates now except Theralase phase 1 study.

And in this study each patients gets two treatments (each treatment about 6 months apart). The phase one study patients only received one treatment.

Some undertreated patients will get a full dose for sure!
https://theralase.com/wp-content/uploads/2021/11/3Q-2021-Newsletter.pdf